Illumina (NASDAQ:ILMN) has decided to proceed with a spin-off option for its $7.1B acquisition, Grail, after EU officials ordered the U.S. genomics company to divest the cancer test developer it acquired in 2021 despite antitrust concerns.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,